The UK and US have announced a important bilateral deal that will ensure no duties on British drug shipments being sold in the US market.
Key Provisions of the Pact
As part of the deal, the UK has committed to raise funding on medicines through the public health system. This commitment guarantees that tariffs on these vital exports will be held at zero for a duration of 36 months.
This agreement follows previous threats to significantly raise tariffs on patented drug products, with increases floated reaching 100%.
"This deal with the UK reinforces the global environment for innovative medicines and introduces much-needed fairness to transatlantic pharmaceutical trade," a release declared.
Economic Significance
Drugs constitute one of the Britain's biggest export categories to the America, which is by far the biggest market for large UK drugmakers.
Statistics reveal that in the year leading up to the third quarter, the UK sold pharmaceutical products valued at £11.1bn to the US. This value represented a significant portion of British export trade in that span.
"This deal secures employment, increases funding and paves the way for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The deal entails several specific pledges from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to control costs will be capped at 15%. Previously, rebates topped twenty percent.
Recent Tensions
The deal comes amid a long-running tension between the drug companies and the UK government over spending levels and regulatory access.
The disagreement were exacerbated by assertions that US consumers were charged a premium for the identical medicines than people in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar investments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
